Clinical Trials | April 30, 2026
Zealand Pharma and Roche charge into Phase 3 with obesity drug bet
The Danish biotech company confirmed the global study will begin in the second half of 2026
The Danish biotech company confirmed the global study will begin in the second half of 2026
After Phase 3 results show major hair regrowth gains
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
The submission is backed by positive results from the Phase 3 AFFIRM study
_256_384.jpg)
The approval makes Cipla’s product the first AB-rated generic therapeutic equivalent of Ventolin HFA
New model focuses on continuity of care, combining therapy, routine and social engagement to support long-term recovery
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
Approval for Albuterol Sulfate inhalation aerosol enables Cipla Limited to enter the $1.5 billion U.S. albuterol market
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
Subscribe To Our Newsletter & Stay Updated
